Aclaris Therapeutics, Inc.(ACRS)
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
Snapshot
$4.32
- 52-Week Range
- $1.34 – $5.15
- YTD
- +50.00%
- IV Rank (30D)
- 2.59
- Straddle Price
- $0.93
- P/C Vol Ratio
- 0.23
- Market Cap
- $0.6B
Fair Value
-50.0% vs price
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 0.5% and dividend payments are stable.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.53% |
| Beta vs SPY | 1.00 |
| Cost of Equity (CAPM) | 10.03% (VRP-adj) |
| WACC | 10.01% |
| Volatility Risk Premium | +105.9pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +12.3% |
| DCF Horizon | 10 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.10 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.1B |
| Return on Equity (TTM) | -48.5% |
| Book / Price | 26.5% |
| Gross Margin (TTM) | 76.3% |
| FCF Margin (TTM) | -621.3% |
| Debt / Equity | 0.00 |
| Quality Score | 2/6 — normal (10y DCF) |
| SMA 50 | $4.40 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $4.48 |
| Bollinger Width / SMA20 | 302.2% (drives anchor stability) |
| Net Debt | $-0.0B |
| Market Cap | $1B |
Peers used for multiples: ALKS, CCCC, CYRX, IART, KALV, OVID, XOMA
(filtered from 8 ETF-co-members; sector bias active)
Blended Fair Value
$1.55
Current Price
$4.32
Deviation
-50.0%
Forward-Return Rank
SHORT
gated
?
| Horizon | Expected α | z Pred | Blended z | Rank % | Active? |
|---|---|---|---|---|---|
| 21d | -2.8% | +0.05 | -1.15 | 6.5% | — |
| 42d | +1.5% ⚠ | +1.41 | -1.15 | 6.5% | — |
| 63d | +1.5% ⚠ | +1.14 | -1.15 | 6.5% | — |
Expected α = forward-return point estimate vs SPY (e.g., +7.5% means the predictor expects this stock to outperform SPY by 7.5% over that horizon).
For SHORT direction the model uses a different ranking metric (conviction-weighted deviation, not the LGBM prediction); Expected α is shown for reference.
⚠ flags rows where Expected α disagrees with the FV direction — two independent signals are in conflict; conviction is low even if rank looks extreme.
Forward-Return Rank. A proprietary ensemble of a machine-learning forward-return model and a conviction-weighted fundamental score, ranked cross-sectionally each day across the S&P 500 (and broader universes on the screener). Each stock is scored at three horizons (21/42/63 trading days). "Active" = top/bottom 5% AND all risk filters pass. Backtested mean alpha vs SPY on active picks: 21d LONG +13.4%, 63d +34.9% (S&P 500, walk-forward). Past performance is not indicative of future results.
Value vs momentum conflict ⚠. The "FV direction" (long/short) comes from the fundamentals-based engine — price vs intrinsic value. The "Expected α" comes from a separate machine-learning predictor trained on ~12 features (sector, options-implied move, beta, institutional flow, etc.). Sometimes the two disagree: a stock is overvalued by fundamentals but the predictor expects it to keep outperforming (sector or momentum tailwinds). When all 3 horizons disagree, treat the direction signal as low-conviction — neither model is strongly recommending a position.
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 26.2× · 3 peers |
| Peer EV/EBITDA | n/a | 0% | median 36.6× · 3 peers |
| Peer P/B | $2.30 | 50% | median 2.0× · 6 peers |
| Peer P/S | $0.80 | 50% | median 10.8× · 7 peers |
| Market Anchor (SMA50) | $4.40 | 0% | stability 0% (BB-width) |
| Options Expected (B-L 30d) | n/a | 0% |
As of 2026-06-12 · updated 2026-06-12 20:59:55.687000
Info
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834)
- Exchange
- XNAS
- Market Cap
- $0.6B
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally…
Price History
Seasonality
| Month | Avg Return | Years of Data |
|---|---|---|
| Jan | -1.29% | 6 |
| Feb | -5.71% | 6 |
| Mar | -3.39% | 6 |
| Apr | -4.08% | 6 |
| May | -4.88% | 6 |
| Jun | +2.52% | 6 |
| Jul | +5.76% | 5 |
| Aug | -0.51% | 5 |
| Sep | -1.98% | 5 |
| Oct | +7.79% | 5 |
| Nov | +3.90% | 5 |
| Dec | +2.87% | 5 |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $4.45
SMA 50: $4.40
SMA 200: $3.19
Current: $4.32
EMA 12: $4.39
EMA 26: $4.43
MACD: -0.0394 | Signal: -0.0432
BULLISH
ADX (14): 12.95
RANGE
+DI: 16.35
−DI: 17.58
Momentum Oscillators
RSI (14): 46.96
NEUTRAL
Stoch %K: 26.91
Stoch %D: 19.19
Williams %R: -64.67
Volume & Volatility
BB Upper: $4.73
BB Lower: $4.18
NEUTRAL
OBV: 120,569,830
Vol SMA 20: 1,111,999
Vol ROC: -5.91%
ATR: $0.25
True Range: $0.24
HV 20: 62.8%
HV 30: 58.6%
HV 60: 66.6%
Data Summary
Data Points: 500
Last Updated: 2026-06-13T13:41:17.882000
Date Range: 2024-06-14T00:00:00 – 2026-06-12T00:00:00
AI Analysis
Choose Frenzy-Fast™ for quick analysis or Frenzy-Pro™ for comprehensive analysis.
Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.
News
Earnings History
8 of 8 under expected move
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2024-08-07 | Pre-Market | 19.84% | 3.17% | 0.16x | Within |
| 2024-11-06 | Pre-Market | 29.07% | 5.58% | 0.19x | Within |
| 2025-02-27 | Pre-Market | 183.25% | 6.80% | 0.04x | Within |
| 2025-05-08 | After-Close | 247.15% | 3.42% | 0.01x | Within |
| 2025-08-07 | Pre-Market | 195.16% | 1.29% | 0.01x | Within |
| 2025-11-06 | After-Close | 18.72% | 2.20% | 0.12x | Within |
| 2026-02-26 | After-Close | 22.54% | 7.19% | 0.32x | Within |
| 2026-05-07 | Pre-Market | 13.60% | 1.67% | 0.12x | Within |
Options Activity
- IV Rank (30D)
- 2.59
- IV Rank (7D)
- 100
- Avg IV
- 121.9%
- Straddle (30D)
- $0.93
- Straddle (7D)
- $0.82
- P/C Volume
- 0.23
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR25 and BF25 from the live options chain. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Volatility Surface
Enter a ticker to render the implied volatility surface.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
- Beta (1Y vs SPY)
- 0.59
- Correlation (SPY)
- 7.5%
- R²
- 0.01
- Ann. Volatility
- 97.4%
- SPY Volatility
- 12.3%
Low volatility - stock moves less than market
Beta & Alpha Over Time
Institutional Ownership (13F)
Latest filings — 2026-03-31
? 13F Guide
Diluted shares outstanding: 124,143,767 (as of 2026-03-31)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
6 filers$2.57M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | CITADEL ADVISORS LLC Custodian | $1.75M | 68.11% | 2026-03-31 |
| 2 | JANE STREET GROUP, LLC Custodian | $345.75K | 13.46% | 2026-03-31 |
| 3 | SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian | $321.00K | 12.50% | 2026-03-31 |
| 4 | SIMPLEX TRADING, LLC Custodian | $73.12K | 2.85% | 2026-03-31 |
| 5 | IMC-Chicago, LLC Custodian | $49.12K | 1.91% | 2026-03-31 |
| 6 | GROUP ONE TRADING LLC Custodian | $30.00K | 1.17% | 2026-03-31 |
4 filers$1.14M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian | $505.88K | 44.45% | 2026-03-31 |
| 2 | CITADEL ADVISORS LLC Custodian | $383.62K | 33.71% | 2026-03-31 |
| 3 | SIMPLEX TRADING, LLC Custodian | $244.50K | 21.48% | 2026-03-31 |
| 4 | GROUP ONE TRADING LLC Custodian | $4.12K | 0.36% | 2026-03-31 |
Insider Activity
Latest: 2026-06-08
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-06-08 | MAXINE GOWEN | Director | Exer (M) | +11,580 | — | EDGAR | |
| 2026-06-08 | VINCENT MILANO | Director | Exer (M) | +11,580 | — | EDGAR | |
| 2026-06-08 | ANDREW N SCHIFF | Director | Exer (M) | +11,580 | — | EDGAR | |
| 2026-06-08 | Christopher P. Molineaux | Director | Exer (M) | +11,580 | — | EDGAR | |
| 2026-06-08 | Anand Mehra | Director | Exer (M) | +11,580 | — | EDGAR | |
| 2026-06-08 | William D. Humphries | Director | Exer (M) | +11,580 | — | EDGAR | |
| 2026-05-05 | Jesse Wayne Hall | Chief Medical Officer | Mixed | +27,045 | $4.41 | -$41.1K | EDGAR |
| 2026-04-27 | Braden Michael Leonard | 10%+ Owner | Sell (S) | −300,000 | $4.53 | -$1.36M | EDGAR |
| 2026-03-03 | Kevin Balthaser | Chief Financial Officer | Mixed | +1,698 | $2.87 | -$1.9K | EDGAR |
| 2026-02-06 | Roland Wilhelm Kolbeck | Chief Scientific Officer | Grant (A) | +430,600 opt | — | EDGAR | |
| 2026-02-06 | James Loerop | Chief Business Officer | Grant (A) | +439,600 opt | — | EDGAR | |
| 2026-02-06 | Kevin Balthaser | Chief Financial Officer | Grant (A) | +445,900 opt | — | EDGAR | |
| 2026-02-06 | Hugh M. Davis | President and COO | Grant (A) | +432,400 RSU | — | EDGAR | |
| 2026-02-06 | Neal Walker | CEO | Grant (A) | +1,236,500 opt | — | EDGAR | |
| 2026-02-06 | Jesse Wayne Hall | Chief Medical Officer | Grant (A) | +441,400 opt | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
Insider Holdings
37 insiders · @ $4.32
Officers, directors, and 10%+ owners ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Braden Michael Leonard | 10%+ Owner | 13,950,000 | $60.26M | $4.23M | 8 | 2026-04-27 |
| 2 | Albert Cha | Director | 4,191,397 | $18.11M | $5.15M | 3 | 2016-07-01 |
| 3 | Vivo Ventures Fund VII, L.P. | 10%+ Owner | 4,101,997 | $17.72M | $15.00M | 1 | 2015-10-13 |
| 4 | Deerfield Special Situations Fund, L.P. | 3,159,165 | $13.65M | -$19.84M | 3 | 2019-07-01 | |
| 5 | Anand Mehra | Director | 2,637,976 | $11.40M | -$11.19M | 18 | 2026-06-08 |
| 6 | RA Capital Healthcare Fund LP | 10%+ Owner | 2,586,190 | $11.17M | $465.2K | 1 | 2016-01-20 |
| 7 | RA CAPITAL MANAGEMENT, L.P. | 10%+ Owner | 2,469,552 | $10.67M | $59.06M | 3 | 2015-10-30 |
| 8 | Sofinnova Management VIII, L.L.C. | 10%+ Owner | 2,289,480 | $9.89M | $22.50M | 1 | 2015-10-13 |
| 9 | Peter Kolchinsky | 10%+ Owner | 2,125,769 | $9.18M | -$32.95M | 5 | 2016-09-19 |
| 10 | FMR LLC | 10%+ Owner | 1,931,727 | $8.35M | $3.61M | 6 | 2016-12-21 |
| 11 | Neal Walker | CEO | 1,562,497 | $6.75M | -$5.20M | 53 | 2026-02-06 |
| 12 | DEERFIELD PARTNERS, L.P. | 10%+ Owner | 1,411,628 | $6.10M | $0 | 2 | 2019-01-02 |
| 13 | James E Flynn | 10%+ Owner | 1,166,959 | $5.04M | -$18.83M | 1 | 2019-05-13 |
| 14 | DEERFIELD MANAGEMENT COMPANY, L.P. | 10%+ Owner | 1,072,775 | $4.63M | -$38.4K | 2 | 2019-06-26 |
| 15 | Stephen A. Tullman | Director | 571,471 | $2.47M | $739.8K | 8 | 2018-10-05 |
| 16 | ANDREW N SCHIFF | Director | 459,995 | $1.99M | -$1.15M | 19 | 2026-06-08 |
| 17 | Joseph Monahan | Chief Scientific Officer | 282,188 | $1.22M | -$2.14M | 21 | 2025-03-04 |
| 18 | Stuart Shanler | Chief Scientific Officer | 273,355 | $1.18M | $0 | 10 | 2019-03-04 |
| 19 | Christopher Powala | Chief Reg & Develop Officer | 272,163 | $1.18M | $0 | 9 | 2019-02-05 |
| 20 | Frank Ruffo | Chief Financial Officer | 201,883 | $872.1K | -$2.81M | 29 | 2022-03-14 |
| 21 | Kevin Balthaser | Chief Financial Officer | 188,130 | $812.7K | $51.4K | 16 | 2026-03-03 |
| 22 | James Loerop | Chief Business Officer | 188,008 | $812.2K | $40.7K | 13 | 2026-02-06 |
| 23 | Kamil Ali-Jackson | Chief Legal Officer | 153,114 | $661.5K | -$3.27M | 32 | 2022-01-05 |
| 24 | David N. Gordon | Chief Medical Officer | 147,447 | $637.0K | -$1.19M | 10 | 2021-07-14 |
| 25 | Vivo Ventures VII Affiliates Fund, L.P. | 10%+ Owner | 79,635 | $344.0K | -$62.28M | 2 | 2016-11-18 |
| 26 | Christopher P. Molineaux | Director | 69,536 | $300.4K | $38.0K | 19 | 2026-06-08 |
| 27 | VIVO VENTURES VII, LLC | 10%+ Owner | 60,972 | $263.4K | -$39.29M | 1 | 2017-03-02 |
| 28 | Hugh M. Davis | President and COO | 45,425 | $196.2K | $0 | 5 | 2026-02-06 |
| 29 | William D. Humphries | Director | 45,105 | $194.9K | $0 | 13 | 2026-06-08 |
| 30 | Douglas J. Manion | Pres and CEO | 41,813 | $180.6K | $99.8K | 6 | 2024-01-03 |
| 31 | Andrew Kenneth William Powell | Director | 33,523 | $144.8K | $27.5K | 14 | 2024-06-04 |
| 32 | MAXINE GOWEN | Director | 33,334 | $144.0K | $0 | 10 | 2026-06-08 |
| 33 | VINCENT MILANO | Director | 28,896 | $124.8K | $0 | 9 | 2026-06-08 |
| 34 | Bryan M. Reasons | Director | 28,732 | $124.1K | $0 | 8 | 2024-06-04 |
| 35 | Jesse Wayne Hall | Chief Medical Officer | 27,045 | $116.8K | $0 | 3 | 2026-05-05 |
| 36 | Brett Fair | Chief Commercial Officer | 10,582 | $45.7K | $0 | 4 | 2019-02-05 |
| 37 | Gail Cawkwell | Chief Medical Officer | 9,593 | $41.4K | $0 | 3 | 2023-07-05 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
ETF Holders
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
| P/B Ratio | 4.2 |
| P/S Ratio | 72.9 |
| EV/EBITDA | -7.5 |
| TTM Revenue | $0.0B |
| TTM Net Income | $-0.1B |
| TTM EPS | $-0.56 |
| ROE | -48.5% |